AU Patent

AU2021286278C1 — Methods for treating ocular diseases

Assigned to Novartis AG · Expires 2024-05-23 · 2y expired

What this patent protects

C:\temp\9ddfdd3e-dl86-4275-bc6c-6f61dbfe3558.docx-14/1 2/2021 METHODS FOR TREATING OCULAR DISEASES Abstract A method is provided for treating a patient having a neovascular ocular disease.

USPTO Abstract

C:\temp\9ddfdd3e-dl86-4275-bc6c-6f61dbfe3558.docx-14/1 2/2021 METHODS FOR TREATING OCULAR DISEASES Abstract A method is provided for treating a patient having a neovascular ocular disease.

Drugs covered by this patent

avacincaptad-pegol-sodium (AVACINCAPTAD PEGOL SODIUM)

Patent Metadata

Patent number: AU2021286278C1
Jurisdiction: AU
Classification: —
Expires: 2024-05-23
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.